



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

October 22, 2013 6:00 – 8:30 p.m.

- 1. Executive Session** **6:00 - 6:30**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

- 2. Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)

- 3. DVHA Pharmacy Administration Updates** **6:35 - 6:45**
 - Updates

- 4. Medical Director Update** **6:45 - 6:50**
 - Clinical Programs Update
 - Prescriber Comments

- 5. Follow-up Items from Previous Meetings** **6:50 - 7:05**
 - Buprenorphine and Opiates
 - Long Acting Injectable Antipsychotic Medications
 - Pulmonary: Short Acting Beta-Agonist Inhalers

- 6. RetroDUR/DUR** **7:05 – 7:25**
 - Buprenorphine and Benzodiazepines

- 7. Clinical Update: Drug Reviews** **7:25 – 7:55**
(Public comment prior to Board action)
 - Abbreviated New Drug Reviews**
 - Cystaran[®] (cysteamine) Ophthalmic Solution
 - Diclegis[®] (doxylamine succinate/pyridoxine) DR Oral Tablet
 - Namenda[®] XR (memantine) Oral Capsule
 - Prolensa[®] (bromfenac 0.07 %) Ophthalmic Solution
 - Simbrinza[®] (brinzolamide 1 %/ brimonidine 0.2 %) Ophthalmic Suspension

 - Full New Drug Reviews**
 - Invokana[®] (canagliflozin) Oral Tablet

- 8. Therapeutic Drug Classes – Periodic Review** **7:55 – 8:20**
(Public comment prior to Board action)
Class review documents available on DVHA web site 10/22/2013 @ Noon
- Acne Medications: Topical
 - Anti-hypertensives: Angiotensin Converting Enzyme (ACE) Inhibitors and Combinations
 - Anti-hypertensives: Angiotensin Receptor Blockers and Combinations
 - Gastrointestinal: H2 Receptor Antagonists
 - Otic: Anti-Infectives
 - Renal: Phosphate Binders
 - Vitamins: Prenatal
- 9. New Managed Therapeutic Drug Classes** **8:20– 8:20**
(Public comment prior to Board action)
- None
- 10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** **8:20 – 8:25**
(Public comment prior to Board action)
- Anti-diabetics: DPP4 Inhibitors (1/1/2014)
 - Anti-infectives: Antivirals: Influenza Vaccines
 - Anti-infectives: Cephalosporins: 3rd Generation (1/1/2014)
 - Gastrointestinals: Proton Pump Inhibitors (1/1/2014)
 - Pulmonary: Corticosteroids: Intranasal (1/1/2014)
- 11. General Announcements** **8:25– 8:30**
Selected FDA Safety Alerts
- Acetaminophen: Drug Safety Communication - Association with Risk of Serious Skin Reactions
 - Gilenya: Drug Safety Communication - Possible PML Case in Europe
 - Olmesartan Medoxomil: Drug Safety Communication - Label Changes To Include Intestinal Problems (Sprue-Like Enteropathy)
 - Zyprexa Relprevv (Olanzapine Pamoate): Drug Safety Communication - FDA Investigating Two Deaths Following Injection
- 12. Adjourn** **8:30**